Related posts
Markets sink on hot inflation numbersMarkets rally to strongest week this yearTSX, Amazon rallyThis summary was created by AI, based on 4 opinions in the last 12 months.
Jamieson Wellness Inc. (JWEL-T) has been considered as a good addition to small- and mid-cap portfolios due to the recent bargains created by fund redemptions. The company is Canada's #1 brand in its sector with a significant market share and a consistent track record of increasing sales and profits. However, a recent disappointing earnings report and lowered guidance resulted in a sell-off by some experts, with concerns about the company's fundamentals. The stock has faced challenges in gaining investor interest despite its potential for growth in the US and Chinese markets.
Canada's #1 brand in its sector, has 25% market share. Went public 6-7 years ago, and increased sales and profits every year. US acquisition should accelerate growth. Now controls direct distribution in China. Cheaper than ever at 18x earnings, but growth prospects are better than ever. High margin, high quality, steady. Great entry point. Yield is 2.32%.
(Analysts’ price target is $43.53)He sold it after a recent disappointing earnings report (lowered their guidance a lot). After all, they're not in a cyclical business. Their acquisition of a Chinese company was interesting, though the structure was unusual--they bought $100 million in preferred shares with warrants but no dividend and took a minority share in the Chinese business. That was the right move in the Chinese market. Otherwise, JWEL's fundamentals didn't impress him. The stock isn't getting much love these days.
Sold off, as investors assumed a pandemic bump. Sales continue to grow organically. Continues to gain market share. US acquisition lets them accelerate growth. Expanding dramatically in China. 19x earnings. Very high quality company.
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. EPS at 34 cents that beat estimates by 2%. Sales of $112.3M were reported. Generally a good quarter. The focus on post covid health trends continue to be a tailwind. Attractive here. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Revenues beat street estimates by 4%. EBITDA was 2% better at $29M. It is trading at 26x earnings, which is reasonably considering the high growth expectations. There are competitors but they have strong market share. A higher risk buy for growth and some income. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Business has reamiend good and earnings growth continues to be expected. They raised dividends in August with more room to grow. The $6 decline is probably over done. Unlock Premium - Try 5i Free
Jamieson Wellness is a Canadian stock, trading under the symbol JWEL-T on the Toronto Stock Exchange (JWEL-CT). It is usually referred to as TSX:JWEL or JWEL-T
In the last year, 3 stock analysts published opinions about JWEL-T. 2 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Jamieson Wellness.
Jamieson Wellness was recommended as a Top Pick by on . Read the latest stock experts ratings for Jamieson Wellness.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
3 stock analysts on Stockchase covered Jamieson Wellness In the last year. It is a trending stock that is worth watching.
On 2024-04-24, Jamieson Wellness (JWEL-T) stock closed at a price of $26.17.
That's right. They've been severely beaten up over the last few years. Massive outflow of funds out of Canada, and it hits the smaller stocks even more. A lot of retail investors put in fund redemptions last year, so that created many bargains.
Over the last 6 months, he added to many of his small- and mid-cap positions. Companies like QTRH, JWEL, and EQB.